This supportive care single-group study (n=200) will test whether regular use of the Apollo wearable (TVS) improves sustained remission rates from PTSD following MDMA-assisted psychotherapy.
This single-group supportive care study provides an Apollo wearable (transcutaneous vibratory stimulation, 10–200 Hz) to participants who completed MAPS MDMA‑assisted psychotherapy to assess effects on PTSD symptoms, mood, anxiety and emotion regulation.
Participants receive the device and app, are instructed to use it daily (≥30 minutes morning and evening), and complete monthly online questionnaires for two years. The study is independent of MAPS.
Participants who completed MAPS MDMA‑assisted psychotherapy will use the Apollo wearable TVS device daily; instruction and app provided.
Apollo wearable TVS (10–200 Hz); wear daily, at least 30 minutes after waking and at least 30 minutes before bed; intensity set at sensory threshold and adjustable by participant.